Pancreatic schwannoma: a case report and an updated 40-year review of the literature yielding 68 cases

Yuntong Ma 1,2†, Bingqi Shen 1†, Yingmei Jia 1†, Yanji Luo 1, Yisu Tian 1, Zhi Dong 1, Wei Chen 3*, Zi-Ping Li 1* and Shi-Ting Feng 1*

Abstract

Background: Pancreatic schwannoma is a rare tumor. Preoperative diagnosis of pancreatic schwannoma is challenging due to its tendency to mimic other lesions of the pancreas. We describe a case of pancreatic schwannoma and present a review of the cases currently reported in the English literature to identify characteristics of pancreatic schwannoma on imaging.

Case presentation: A 53-year-old male presented with a history of intermittent periumbilical abdominal pain and lower back pain for 1 week. Based on ultrasound (US) and computed tomography (CT) findings, we made a preoperative diagnosis of solid pseudopapillary tumor and performed a standard pancreaticoduodenectomy. Pathological examination showed that the tumor was composed of spindle cells with a palisading arrangement, and immunohistochemistry revealed strong positive staining for S-100 protein, which was consistent with a diagnosis of pancreatic schwannoma. At the 8-month follow-up visit, the patient was doing well without recurrent disease, and his abdominal pain had resolved.

Conclusions: Although pancreatic schwannoma is rare, it should be included in the list of differential diagnoses of pancreatic masses, both solid and cystic. A tumor size larger than 6.90 cm, vascular encasement, or visceral invasion should elicit suspicion of malignant transformation.

Background

Schwannomas, also known as neurilemmomas, are neoplasms arising from the Schwann cells of peripheral nerve sheaths [1, 2]. Schwannomas most frequently involve the head and neck area, major nerve trunks, and flexor aspects of the extremities. Deeply situated schwannomas are predominantly found in the retroperitoneum and posterior mediastinum but are rarely found in the trunk and gastrointestinal tract [1]. Pancreatic schwannomas are an extremely unusual variant of this neoplasm. According to a PubMed database search, 67 cases of pancreatic schwannomas have been described in the English literature over the past 40 years [3–64].

It has been reported that degenerative changes, such as cyst formation, hemorrhage, calcification, hyalinization and xanthomatous infiltration, are found in approximately two-thirds of pancreatic schwannomas [5, 6]. Degenerative changes lead to the presence of obvious variety in the appearance and size of the tumors. Preoperative diagnosis of pancreatic schwannoma can be particularly challenging. Pancreatic schwannomas may mimic other, more common pancreatic lesions, such as cystic neoplasms, solid and pseudopapillary neoplasms, pseudocysts and neuroendocrine tumors. Therefore, pancreatic schwannomas have a very high rate of misdiagnosis. Furthermore, schwannomas are benign peripheral nerve sheath tumors (PNSTs) by strict definition. However, they can undergo malignant degeneration, in which case they are called malignant PNSTs (MPNSTs) [6–11]. Simple enucleation is usually sufficient for benign pancreatic schwannomas, while
extensive radical resection is recommended for patients with malignant tumors. However, how to distin-
guish malignant from benign pancreatic schwannomas remains challenging.

Consequently, a clearer consensus on the characteristics of pancreatic schwannomas is needed. For this purpose, we present herein a case of pancreatic schwannoma in a 53-year-old male and a review of the previous literature with an emphasis on radiographic features that may help distinguish between benign and malignant tumors.

Case presentation
A 53-year-old male presented to our hospital in June 2016 with a history of intermittent periumbilical abdominal pain and lower back pain for 1 week. He did not exhibit any nausea/vomiting, jaundice or weight loss. Upon physical examination, the abdomen was soft and non-distended without evidence of hepatosplenomegaly or a palpable mass. His family history was not significant, and tumor markers (AFP, CA-125, CA19–9, and CEA) were within normal ranges.

An abdominal US revealed a well-defined, hypoechoic mass in the head of the pancreas that measured 4.8 × 4.7 cm and contained an internal cystic component. On contrast-enhanced US, there was uniform enhancement of the tumor, and no intratumoral vascularity was detected with Doppler imaging (Fig. 1). Unenhanced computed tomography (CT) demonstrated a well-encapsulated, heterogeneous lesion at the junction of the pancreatic head and neck without calcification. On contrast-enhanced CT, there was mild and heterogeneous enhancement in the solid component of the tumor, which was less than the surrounding pancreatic parenchyma. The internal cystic component was not enhanced (Fig. 2). The mass compressed nearby blood vessels, such as the portal vein and celiac trunk, without invading them. No associated dilatation of the main pancreatic duct or common bile duct was found. Additionally, there were no liver masses or pathologic lymphadenopathy.

According to these results, the mass was preliminarily considered as a solid pseudopapillary tumor of the pancreas. The patient underwent exploratory laparotomy, which disclosed a well-encapsulated 6 × 5 cm mass arising from the head of the pancreas and compression of the portal and superior mesenteric veins. A standard Whipple pancreaticoduodenectomy was performed.

Histopathological examination of the resected specimen revealed a 5.5 cm, well-circumscribed, yellow-gray mass with a slightly hard consistency. Microscopically, the tumor was completely surrounded by a capsule with subcapsular lymphocytic infiltrates and abundant lymphoid follicle formation. The tumor was composed of spindle cells with wavy nuclei and mild atypia exhibiting a palisading arrangement. Nerve fiber bundles were noted at the periphery (Fig. 3). Immunohistochemical staining results revealed that the tumor was strongly positive for CD-56 and S-100 but negative for CD-117, CD-34, DOG-1, desmin or smooth muscle actin. These findings were consistent with the final diagnosis of pancreatic schwannoma.

Postoperatively, the patient recovered well, and he was discharged without incident 3 weeks after the operation. At the 8-month follow-up visit, the patient was doing well without recurrent disease, and his abdominal pain had resolved.
Discussion

Schwannomas, which were first described by Verocay in 1910, are mesenchymal neoplasms derived from Schwann cells that line peripheral nerve sheaths and do not contain neuroganglion cells [65]. However, the pancreas is an extremely uncommon site of origin for schwannomas, which arise from either the sympathetic or parasympathetic nerve fibers coursing through the pancreas [29]. A literature search was performed in March 2017. The MeSH term used in the PubMed search was 'pancreatic schwannoma'. In addition, the reference lists of relevant articles were searched to find other eligible studies. A PubMed search of the past four decades revealed 62 articles describing 67 cases of pancreatic schwannoma in the English literature [3–64]. A total of 68 cases of pancreatic schwannoma, including our current case, were analyzed and summarized. The clinicopathological data for all 68 patients with pancreatic schwannoma was shown in Table 1. All of the data were analyzed with SPSS 17.0 software (Chicago, IL, USA). Continuous variables were recorded as the means ± standard deviation (SD) and range and were analyzed using a two-tailed Student’s t-test. The tumor distribution was skewed in the control group, so the Wilcoxon rank sum test of two independent samples was used. Categorical variables were analyzed with the four-fold table method and the R² method of the Chi-squared test. P values <0.05 were considered statistically significant. Receiver-operating characteristic (ROC) curves were used to determine the optimal cut-off points of tumor size for distinguishing malignant lesions from benign lesions.

Pancreatic schwannomas may develop in any part of the pancreas but are most commonly located in the pancreatic head. Overall, approximately one-third of patients are asymptomatic. Common symptoms are abdominal pain and weight loss, while a few patients present with nausea, vomiting, dyspepsia, back pain or a palpable mass. Anemia, melena and jaundice are infrequent symptoms. Laboratory tests, including tumor markers, are usually within the normal range. Pancreatic schwannomas are usually benign and solitary. However, there may be...
multiple malignant schwannomas in patients with von Recklinghausen disease (VRD) [61]. In the 68 cases in this review, only 2 patients reported a history of VRD [7, 11]. Definitive diagnosis is achieved only with histological examination and immunohistochemical staining of a surgically resected specimen. Macroscopically, pancreatic schwannomas are well-circumscribed, encapsulated, homogeneous, yellow-tan nodules. Up to two-thirds of pancreatic schwannomas exhibit secondary degenerative changes, such as cyst formation, hemorrhage, hyalinization, calcification and xanthomatous infiltration [26, 37, 62]. Microscopically, typical features of pancreatic schwannomas include an organized hypercellular component (Antoni A areas) and a hypocellular component with loose myxoid stroma (Antoni B areas). Antoni B areas often have accompanying degenerative changes [4]. Benign schwannomas normally have < 5 mitotic figures per 10 high-powered fields [58]. Pancreatic schwannomas demonstrate strong positive immunohistochemical staining for S-100, vimentin, and CD-56, and they show negative staining for cytokeratin AE1/AE3, CD34, CD117 (c-kit), desmin, and smooth muscle myosin [66].

An accurate preoperative diagnosis of pancreatic schwannomas is difficult due to the nonspecific radiological

| Table 1 Summary of clinicopathological data from all 68 cases of pancreatic schwannoma [3–64] | Table 1 Summary of clinicopathological data from all 68 cases of pancreatic schwannoma [3–64] (Continued) |
|---|---|
| **Age (years) (n = 68)** | **Treatment (n = 67)** |
| Mean | n (%) or mean ± SD (range) | Solid pseudopapillary neoplasm | n (%) or mean ± SD (range) |
| 55.7 ± 14.7 (20–87) | | Pancreatic neuroendocrine tumor | 7 (20%) |
| Sex (male/female), (male %) (n = 68) | Pseudocyst | 2 (5.7%) |
| 15:19 (44%) | Acinar cell carcinoma | 3 (8.6%) |
| Symptoms (n = 68) | Mucinous cystadenocarcinoma | 6 (17%) |
| Asymptomatic | | | |
| 23 (34%) | | | |
| Symptoms | | | |
| Abdominal pain | | Pancreatoduodenectomy | 16 (24%) |
| 34 (50%) | | Pylorus-preserving | 7 (10%) |
| Weight loss | | pancreaticoduodenectomy | | |
| 12 (18%) | | Central pancreatectomy | 2 (3.0%) |
| Nausea/vomiting | | Distal pancreatectomy +/- splenectomy | 15 (22%) |
| 6 (8.8%) | | Enucleation | 8 (12%) |
| Dyspepsia | | Surgical resection not otherwise specified (NOS) | 14 (21%) |
| 5 (7.4%) | | Unresectable | 2 (3.0%) |
| Back pain | | Refused | 3 (4.5%) |
| 4 (5.9%) | | | |
| Abdominal mass | | | |
| 3 (4.4%) | | | |
| Anemia | | | |
| 2 (2.9%) | | | |
| Melena | | | |
| 2 (2.9%) | | | |
| Jaundice | | | |
| 2 (2.9%) | | | |
| Mean size (cm) (n = 64) | | | |
| 6.1 ± 5.7 (1–33) | | | |
| Location (n = 67) | | | |
| Uncinate | | | |
| 9 (13%) | | | |
| Head | 27 (40%) | | |
| Head + body | 3 (4.5%) | | |
| Body | 14 (21%) | | |
| Body + tail | 7 (10%) | | |
| Tail | 6 (9.0%) | | |
| Nature of tumor on imaging (n = 68) | | | |
| Solid | 19 (28%) | | Benign | 60 (88%) |
| Cystic | 29 (43%) | | Malignant | 8 (12%) |
| Solid + cystic | 15 (22%) | | Mean follow-up (months) (n = 34) | 19 ± 15.4 (3–65) |
| Not specified | 5 (7.4%) | | Died of disease | 1 |
appearance of these tumors, even with the use of multiple imaging modalities. Due to the variable proportions of Antoni A and B areas contained in the tumor, pancreatic schwannomas commonly appear cystic (near half of cases, 29; 43%) but may also have a completely solid structure (19; 28%) or a mixed solid and cystic pattern (15; 22%) (Table 1). Up to 80% of schwannomas exhibited well-defined margins on imaging and were also found to be well encapsulated upon gross pathological examination (Table 1). On ultrasound, a pancreatic schwannoma usually appears as a well-defined, hypoechoic lesion that shows poor contrast intake and is hypoenhanced compared to the surrounding pancreatic parenchyma [22, 44]. On unenhanced CT, tumors composed of exclusively or predominantly Antoni A areas appear as well-defined, heterogeneous, hypodense, solid masses due to their high cellularity and increased lipid content, whereas tumors with high Antoni B areas appear as homogeneous cystic masses due to their low cellularity and loose myxoid stroma [56]. Contrast-enhanced CT is helpful for distinguishing between Antoni A and Antoni B areas based on their vascularity. Generally, the more vascular Antoni A areas are enhanced, whereas Antoni B areas are frequently not enhanced [56, 64]. On magnetic resonance imaging (MRI), schwannomas appear homogeneously hypointense on T1-weighted imaging (T1WI) and hyperintense on T2-weighted imaging (T2WI) [45]. Sometimes, they may also appear inhomogeneously intense due to the presence of a fair amount of both Antoni A and Antoni B areas in the tumors [56, 64].

Calcifications (5; 8.6%) and associated pancreatic ducts or common bile duct dilation (2; 9.1%) are uncommon findings but are both associated with benign tumors. Larger tumors (9; 31%) may cause the compression or displacement of nearby vessels. More rarely, tumors (4; 14%) are found to completely encase adjacent vessels or invade the duodenum and transverse colon (Table 1). Lymph node enlargement and distant metastases are typically not associated with pancreatic schwannomas. Due to the variable radiographic appearance of schwannomas, they often mimic other pancreatic tumors that share similar imaging features, leading to a high rate of misdiagnosis. The most common differential diagnosis is cystic neoplasms, such as serous or mucinous cystic neoplasms. Pancreatic schwannomas are also misdiagnosed as pancreatic neuroendocrine tumors, solid pseudopapillary tumors, mucinous cystadenocarcinomas, acinar cell carcinomas and pancreatic pseudocysts. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) may contribute to precise preoperative diagnosis, but its use remains controversial because of its high false-negative rate. In the 16 patients with EUS-FNA, only 8 (50%) were correctly diagnosed preoperatively with pancreatic schwannoma.

The vast majority of pancreatic schwannomas (approximately 88.2%) are benign [3]. Malignant transformation is extremely rare. Only 8 cases (11.8%) of malignant pancreatic schwannoma have been described in the English literature [6–11]. Some investigators have attempted to correlate the tumor’s characteristics on imaging with its malignant potential. Moriya et al. [4]

Table 2 Comparison of characteristics between benign and malignant pancreatic schwannomas

| Characteristic | Benign (n = 60) | Malignant (n = 8) | P |
|---------------|----------------|-----------------|---|
| Mean age (years) | 56.3 ± 14.4 (20–87) | 51.1 ± 17.7 (24–74) | 0.358 |
| Sex (male/female), (male %) | 9:11 (45%) | 3:5 (37.5%) | 1.000 |
| Mean size (cm) | 5.2 ± 4.0 (1–20) | 14.0 ± 10.3 (5–33) | 0.004 |
| Location | | | |
| Uncinate | 9 (15%) | 0 (0%) | 0.228 |
| Head | 22 (37%) | 5 (71%) | |
| Head + body | 3 (5%) | 0 (0%) | |
| Body | 14 (23%) | 0 (0%) | |
| Body + tail | 6 (10%) | 2 (29%) | |
| Tail | 6 (10%) | 0 (0%) | |
| Nature of tumor on imaging | | | |
| Solid | 17 (30%) | 2 (25%) | 0.845 |
| Cystic | 26 (46%) | 3 (37.5%) | |
| Solid + cystic | 13 (23%) | 2 (25%) | |
| Not specified | 4 (7.1%) | 1 (12.5%) | |
| Imaging characteristics | | | |
| Well-defined margins | 45 (96%) | 2 (33%) | 0.009 |
| Presence of calcifications | 5 (9.4%) | 0 (0%) | 1.000 |
| Pancreatic duct/CBD dilation | 2 (9.1%) | 0 (0%) | 1.000 |
| Relation to nearby structures | | | |
| No changes in nearby structures | 12 (52%) | 0 (0%) | < 0.001 |
| Compressed/displaced vessels | 9 (39%) | 0 (0%) | |
| Encasement of vessels | 2 (8.7%) | 2 (50%) | |
| Invasion of viscera | 0 (0%) | 3 (50%) | |
| Treatment | | | |
| Pancreat icoduodenectomy | 13 (22%) | 3 (37.5%) | |
| Pylorus-preserving pancreaticoduodenectomy | 7 (10%) | 0 (0%) | |
| Central pancreatectomy | 2 (3.0%) | 0 (0%) | |
| Distal pancreatectomy +/- splenectomy | 13 (19%) | 1 (12.5%) | |
| Enucleation | 8 (12%) | 0 (0%) | |
| Surgical resection NOS | 13 (19%) | 2 (25%) | |
| Unresectable | 0 (0%) | 2 (25%) | |
| Refused | 3 (4.5%) | 0 (0%) | |
| Mean follow-up (months) | 19.4 ± 16.0 (3–65) | 16.3 ± 11.6 (4–28) | |
| Died of disease | 0 | 1 | |
reported that larger tumors correlated with greater malignant potential. This was confirmed in our current analysis of an updated dataset. The characteristics of benign and malignant pancreatic schwannomas were summarized in Table 2. Pancreatic schwannomas had a mean size of 5.2 ± 4.0 cm for benign tumors and 14.0 ± 10.3 cm for malignant tumors, a difference that was statistically significant. A ROC curve of tumor size was constructed with an area under the curve calculated as 0.836, a cut-off of 6.90 cm, a sensitivity of 71.4% and a specificity of 75.4% (Fig. 4). We further analyzed other tumor characteristics on imaging to determine the predictors of malignancy on pathological examination. However, there was no correlation between whether tumors appeared to be solid, cystic, or have a mixed pattern as a predictor of malignancy (Table 2). Benign tumors were significantly more likely than malignant ones to exhibit well-defined margins on imaging, whereas the presence of calcifications and pancreatic duct or common bile duct dilation was not significant. However, the presence of well-defined margins did not exclude malignancy because 2 cases of malignant schwannoma were also initially described as having well-defined radiographic margins. Moreover, malignant tumors were more likely than benign tumors to cause changes in adjacent structures, including the encasement of nearby vessels, such as the portal vessels, celiac trunk, and superior mesenteric vessels, as well as the invasion of adjacent organs, such as the small and large bowel on surgical or pathological examination (Table 2).

The management of pancreatic schwannomas is guided by location and histological results. Because most of these tumors are benign and malignant transformation is rare, simple enucleation is usually sufficient if pathology is confirmed before surgery [63]. In cases of large tumors, especially those exhibiting malignant behavior (infiltration of tissue), the presence of intangibility in frozen section or close proximity to major vessels, an oncological margin-negative resection is recommended [6]. In a review of treatments, the most common type of surgical resection was pancreaticoduodenectomy, followed by distal pancreatectomy with/without splenectomy, enucleation, pylorus-preserving pancreaticoduodenectomy, and central pancreatectomy. The high frequency of extensive radical resection may reflect the difficulties in obtaining an accurate preoperative diagnosis of pancreatic schwannomas and in distinguishing these lesions from other pancreatic neoplasms. In such cases, intraoperative frozen sections should be performed to help establish the diagnosis of a benign schwannoma and avoid
more extensive resection [4]. Following tumor excision, the long-term prognosis of pancreatic schwannoma is excellent, with no cases of recurrence over a mean follow-up of 19 ± 15.4 months (range 3–65 months).

**Conclusions**

Although pancreatic schwanna is rare, it should be included in the list of differential diagnoses of pancreatic masses, both solid and cystic. A tumor size larger than 6.90 cm, vascular encasement, or visceral invasion should elicit suspicion of malignant transformation.

**Abbreviations**

AFP: Alpha fetoprotein; CA-125: Carbohydrate antigen 125; CA19–9: Carbohydrate antigen 19–9; CD: Cluster of differentiation; CEA: Carcinoembryonic antigen; CT: Computed tomography; DOG-1: Discovered on GIST-1; EUS-FNA: Endoscopic ultrasound-guided fine needle aspiration; GIST: Gastrointestinal stromal tumor; MRI: Magnetic resonance imaging; PNSTs: Peripheral nerve sheath tumors; ROC curves: Receiver-operating characteristic curves; SD: Standard deviation; T1W: T1-weighted imaging; T2W: T2-weighted imaging; US: Ultrasound; VRD: Von Recklinghausen disease

**Acknowledgments**

Not applicable.

**Funding**

This work was funded by the National Natural Science Foundation of China (81571750), the Natural Science Foundation of Guangdong Province (2014A030311018 and 2015A030313043), and S&T Programs (2014A020212125) of Guangdong Province. The Grants-in-Aid supported this study just financially, and had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets generated during the current study are not publicly available because of patient privacy, but are available from the corresponding author on reasonable request.

**Authors’ contributions**

STF, WC and ZPL designed the research and were responsible for quality control of data. WC performed a standard Whipple pancreaticoduodenectomy. BS, YJ, YT and ZD performed the follow-up control of data. WC performed a standard Whipple operation on patient. STF, WC and ZPL designed the research and were responsible for quality control of data. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Pavlović M, Chourroumouzi D, Kiziridou A, Skordalaki A, Zarampoukas T, Drevelingis A. Imaging of peripheral nerve sheath tumors with pathologic correlation: pictorial review. Eur J Radiol. 2004;52(3):229–39.
2. Skovronsky DM, Oberholtzer JC. Pathologic classification of peripheral nerve tumors. Neurosurg Clin N Am. 2004;15(2):157–66.
3. Xu SY, Sun K, Owusu-Ansaah KG, Xie HY, Zhou L, Zheng SS, et al. Central pancreatectomy for pancreatic schwannoma: a case report and literature review. World J Gastroenterol. 2016;22(37):8439–46.
4. Moriya T, Kimura W, Hirai I, Takehita A, Tezuka K, Watanabe T, et al. Pancreatic schwannoma: case report and an updated 30-year review of the literature yielding 47 cases. World J Gastroenterol. 2012;18(13):1538–44.
5. Pananjape C, Johnson SR, Khwaja K, Goldham D, Kruskal JB, Hanto DW. Clinical characteristics, treatment, and outcome of pancreatic schwannomas. J Gastrointest Surg. 2004;8(6):706–12.
6. Stojanovic MP, Radojkovic M, Jeremic LM, Zlatic AV, Stanojevic GZ, Jovanovic MA, et al. Malignant schwannoma of the pancreas involving transversal colon treated with en-bloc resection. World J Gastroenterol. 2010;16(1):119–22.
7. Coombs RJ. Case of the season. Malignant neurogenic tumor of duodenum and pancreas. Semin Roentgenol. 1990;25(2):127–9.
8. Eggermont A, Vuzevski V, Huisman M, De Jong K, Jeeck J. Solitary malignant schwannoma of the pancreas: report of a case and ultrastructural examination. J Surg Oncol. 1987;36(1):21–5.
9. Liegl B, Bode K, Martin D, Tsymbrovsky O, Lackner K, Beham A. Micrcozystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall. Pathol Int. 2011;61(2):88–92.
10. Moller Pedersen V, Hede A, Graem N. A Solitary malignant schwannoma mimicking a pancreatic pseudocyst: A case report. Acta Chir Scand. 1982;148(8):697–8.
11. Wahl MM, Brandpigel K. Gastrointestinal bleeding due to pancreatic schwannoma complicating von Recklinghausen’s disease. Gastroenterology. 1989;97(6):1550–1.
12. Abu-Zaid A, Azzam A, Abou Al-Shaar H, Alshammary AM, Amin T, Mohammed S. Pancreatic tail schwannoma in a 44-year-old male: a case report and literature review. Case Rep Oncol Med. 2013;2013:416–713.
13. Agganwala G, Satsangi B, Shukla S, Lahoti BK, Mathur RK, Maheshwari A. Rare asymptomatic presentations of schwannomas in early adolescence: three cases with review of literature. Int J Surg Pathol. 2010;18(3):203–6.
14. Akjoshy T, Ueda Y, Yanai K, Yamaguchi H, Kawamoto M, Toyoda K, et al. Melanotic schwannoma of the pancreas: a case report. Surg Today. 2004;34(6):550–3.
15. Almo KM, Traverso LW. Pancreatic schwannoma: an uncommon but important entity. J Gastrointest Surg. 2001;5(4):359–63.
16. Antonini F, Santinelli A, Macari G. Endoscopic ultrasound-guided fine-needle aspiration of an unusual pancreatic mass. Clin Gastroenterol Hepatol. 2015;13(3):e25.
17. Barneri L, Tarantino I, Granata A, Traina M. Endoscopic ultrasound-guided fine-needle aspiration diagnosis of pancreatic schwannoma. Dig Liver Dis. 2013;45(6):523.
18. Brown SZ, Owen DA, O’Connell JX, Scudamore CH. Schwannoma of the pancreas: a report of two cases and a review of the literature. Mod Pathol. 1998;11(12):1178–82.
19. Bui TD, Nguyen T, Huerta S, Gu M, Hsiang D. Pancreatic schwannoma. A case report and review of the literature. JOP. 2004;5(6):520–6.
20. Burd DA, Tyagi G, Bader DA. Benign schwannoma of the pancreas. AJR Am J Roentgenol. 1992;159(3):675.
21. Cilegad N, Arda K, Aksoy M. Pancreatic schwannoma: a case report and review of the literature. Oncol Lett. 2014;8(6):2741–3.
22. Crino SF, Bernardoni L, Manfrini E, Parisi A, Gabbrielli A. Endoscopic ultrasound features of pancreatic schwannoma. Endosc Ultrasound. 2016;5(6):396–8.
23. David S, Barkin JS. Pancreatic schwannoma. Pancreas. 1993;8(2):274–6.
24. Di Benedetto F, Spaggiari M, De Ruvo N, Masetti M, Montalti R, Quinlini C, et al. Pancreatic schwannoma of the body involving the splenic vein: case report and review of the literature. Eur J Surg Oncol. 2007;33(7):926–8.
48. Oshima M, Yachida S, Suzuki Y. Pancreatic schwannoma in a 32-year-old
47. Okuma T, Hirota M, Nitta H, Saito S, Yagi T, Ida S, et al. Pancreatic
44. Nishikawa T, Shimura K, Tsuyuguchi T, Kiyono S, Yokosuka O. Contrast-
43. Mummadi RR, Nealon WH, Artifon EL, Fleming JB, Bhutani MS. Pancreatic
42. Mourra N, Calvo J, Arrive L. Incidental finding of cystic pancreatic
40. Melato M, Bucconi S, Marus W, Spivach A, Perulli A, Mucelli RP. The
39. Liessi G, Barbazza R, Sartori F, Sabbadin P, Scapinello A. CT and MR imaging
38. Li S, Ai SZ, Owens C, Kulesza P. Intrapancreatic schwannoma diagnosed by
37. Lee JS, Kim HS, Jung JJ, Han SW, Kim YB. Ancient schwannoma of the
36. Kinhal VA, Ravishankar TH, Melapure AI, Jayaprakasha G, Range Gowda BC,
33. Hsiao WC, Lin PW, Chang KC. Benign retroperitoneal schwannoma
32. Hirabayashi K, Yasuda M, Umemura S, Itoh H, Itoh J, Yazawa N, et al.
30. Ferrozzi F, Bova D, Garlaschi G. Pancreatic schwannoma: report of three
29. Feldman L, Philpotts LE, Reinhold C, Duguid WP, Rosenberg L. Pancreatic
28. Fasanella KE, Lee KK, Kaushik N. Clinical challenges and images in GI.
27. Ercan M, Aziret M, Bal A, Ş
26. Duma N, Ramirez DC, Young G, Nikias G, Karpeh M, Bamboat ZM. Enlarging
25. Dorsey F, Taggart MW, Fisher WE. Image of the month. Pancreatic schwannoma. Arch Surg. 2010;145(9):913–4.
24. Zafar Z, Baig MA, Zafar S. Clinical significance of cystic pancreatic schwannoma: a case report and review of the literature. Clin Pract. 2013;5(4):793.
23. Oshima M, Yachida S, Suzuki Y. Pancreatic schwannoma: a rare case and a brief literature review. Int J Surg Case Rep. 2016;22:101–4.
22. Fasanella KE, Lee KK, Kaskhish N. Clinical challenges and images in GI. Benign schwannoma of the pancreatic head. Gastroenterology. 2007;132(2):489–90.
21. Ercan M, Aziret M, Bal A, Ş
20. Oshima M, Yachida S, Suzuki Y. Pancreatic schwannoma in a 32-year-old
19. Okuma T, Hirota M, Nitta H, Saito S, Yagi T, Ida S, et al. Pancreatic
18. Nishikawa T, Shimura K, Tsuyuguchi T, Kiyono S, Yokosuka O. Contrast-enhanced harmonic EUS of pancreatic schwannoma. Gastrointest Endosc. 2016;83(2):463
17. Ercan M, Aziret M, Bal A, Ş
16. Oshima M, Yachida S, Suzuki Y. Pancreatic schwannoma in a 32-year-old
15. Okuma T, Hirota M, Nitta H, Saito S, Yagi T, Ida S, et al. Pancreatic
14. Nishikawa T, Shimura K, Tsuyuguchi T, Kiyono S, Yokosuka O. Cystic pancreatic schwannoma: report of two cases and review of the literature. Pancreas. 1997;15(1):99–105.
13. Ferrozzi F, Bova D, Garlaschi G. Pancreatic schwannoma: report of three cases. Clin Radiol. 1995;50(7):492–5.
12. Gupta A, Subhas G, Mittal VK, Jacobs MJ. Pancreatic schwannoma: literature review. J Surg Educ. 2009;66(3):168–73.
11. Hirabayashi K, Yasuda M, Umemura S, Itoh H, Itoh J, Yazawa N, et al. Cytological features of the cystic fluid of pancreatic schwannoma with cystic degeneration. A case report. JOP. 2008;9(2):203–8.
10. Hisao WC, Lin PW, Chang KC. Benign retroperitoneal schwannoma mimicking a pancreatic cystic tumor: case report and literature review. Hepato-Gastroenterology. 1998;45(24):2418–20.
9. J D, R S, K C, Devi NR. Pancreatic schwannoma–a rare case report. J Clin Diagn Res. 2014;8(7):FD01–5.
8. Kim G, Choi YS, Kim HJ, Do JH, Park ES. Pancreatic benign schwannoma combined with hemorrhage in an internal cyst. J Dig Dis. 2011;12(2):138–41.
7. Kinhal VA, Ravishankar TH, Melapure AI, Jayaprakasha G, Rangé Gowda BC, Manjunath BC. Pancreatic schwannoma: report of a case and review of literature. Indian J Surg. 2010;72(Suppl 1):296–8.
6. Lee JS, Kim HS, Jung JJ, Han SW, Kim YB. Ancient schwannoma of the pancreas mimicking a cystic tumor. Virchows Arch. 2001;439(5):697–703.
5. Li S, Ai SZ, Owens C, Kulesza P. Intrapancreatic schwannoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration cytology. Diagn Cytopathol. 2009;37(2):132–5.
4. Liessi G, Barbazza R, Sartori F, Sabbadin P, Scapinello A. CT and MR imaging of melanocytic schwannomas; report of three cases. Eur J Radiol. 1990;1(2):138–42.
3. Melato M, Buccconi S, Marus W, Spivach A, Perulli A, Muccelli RP. The schwannoma: an uncommon type of cystic lesion of the pancreas. Ital J Gastroenterol. 1993;25(7):385–7.
2. Morita S, et al. Pancreatic Schwannoma: report of a case. Surg Today. 1999; 29(10):1093–7.
1. Mouna N, Calvo J, Arrive L. Incidental finding of cystic pancreatic Schwannoma mimicking a Neuroendocrine tumor. Appl Immunohistochem Mol Morphol. 2016;24(2):149–50.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit